Physician profile
Benoit C Pineau
NPI 1619173309
$41,729.58
in general payments reported to CMS, 2019-2025
48 companies · $25K in 2025
The $25K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,034 · 2020: $409 · 2021: $5,633 · 2022: $2,061 · 2023: $2,245 · 2024: $4,831 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $8,672 · Travel and Lodging: $2,028 · Consulting Fee: $1,716 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,162.00 |
| Food and Beverage | $8,671.65 |
| Travel and Lodging | $2,028.00 |
| Consulting Fee | $1,716.00 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20,112.18 | 2022-2025 | Dupixent |
| Abbvie INC. | $6,630.57 | 2019-2025 | |
| Genzyme Corporation | $2,906.39 | 2022-2025 | |
| Medtronic, INC. | $2,829.63 | 2021-2025 | Gi Genius, Endoflip, Interstim |
| Boston Scientific Corporation | $1,204.96 | 2019-2025 | General - Biliary Devices, Exalt Model D |
| Takeda Pharmaceuticals U.S.A., INC. | $997.91 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $980.85 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $853.27 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Allergan, INC. | $605.32 | 2019-2020 | |
| Celgene Corporation | $478.05 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $442.92 | 2021-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $376.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $350.87 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Pfizer INC. | $308.38 | 2020-2025 | |
| Ironwood Pharmaceuticals, INC | $268.41 | 2020-2025 | Linzess |
Show all 46 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benoit Pineau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.